Envestnet Asset Management Inc. Has $12.12 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Envestnet Asset Management Inc. raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 5.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,186 shares of the medical equipment provider's stock after purchasing an additional 6,659 shares during the period. Envestnet Asset Management Inc. owned 0.18% of Lantheus worth $12,121,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Summit Securities Group LLC bought a new stake in shares of Lantheus in the 4th quarter worth approximately $37,000. UMB Bank n.a. grew its position in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 381 shares during the last quarter. Blue Trust Inc. grew its position in Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after purchasing an additional 633 shares during the last quarter. GAMMA Investing LLC grew its position in Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock valued at $128,000 after purchasing an additional 298 shares during the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new stake in Lantheus during the 4th quarter valued at about $125,000. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LNTH has been the topic of several recent research reports. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. B. Riley lowered their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Truist Financial lowered their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Lantheus has an average rating of "Moderate Buy" and an average target price of $131.20.

Lantheus Stock Up 0.6%

Shares of LNTH stock traded up $0.45 during trading hours on Tuesday, reaching $72.01. 412,203 shares of the company's stock were exchanged, compared to its average volume of 981,570. Lantheus Holdings, Inc. has a 1 year low of $69.12 and a 1 year high of $118.21. The stock has a market cap of $4.98 billion, a PE ratio of 20.43 and a beta of 0.12. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The stock's fifty day moving average price is $78.80 and its two-hundred day moving average price is $89.44.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.69 earnings per share. Research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.00% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.